Invitae Corp (NVTA) Files Form 4 Insider Selling : Patty Dumond Sells 1,000 Shares

Invitae Corp (NVTA): Patty Dumond , VP Fin. & Principal Acct. Off. of Invitae Corp sold 1,000 shares on Jul 14, 2016. The Insider selling transaction was reported by the company on Jul 15, 2016 to the Securities and Exchange Commission. The shares were sold at $8.79 per share for a total value of $8,790.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 20, 2016, Patty Dumond (VP Fin. & Principal Acct. Off.) sold 1,000 shares at $8.00 per share price.On Mar 2, 2016, Lisa Alderson (Chief Strategy Officer) sold 5,000 shares at $9.05 per share price.Also, On Aug 13, 2015, Sean E George (COO) purchased 49,899 shares at $9.12 per share price.

InVitae Corp: On Friday, Jul 15, 2016 heightened volatility was witnessed in InVitae Corp which led to swings in the share price. The shares opened for trading at $8.46 and hit $8.69 on the upside , eventually ending the session at $8.61, with a gain of 3.11% or 0.26 points. The heightened volatility saw the trading volume jump to 39,344 shares. The 52-week high of the share price is $13.28 and the company has a market cap of $276 M . The 52-week low of the share price is at $5.66.

InVitae Corp Money Flow Index Chart

Company has been under the radar of several Street Analysts.InVitae Corp is Initiated by The Benchmark Company to Hold and the brokerage firm has set the Price Target at $8.50. The Rating was issued on Jun 30, 2016.

Invitae Corporation is a company that utilizes an integrated portfolio of laboratory processes software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples analyze information about patient-specific genetic variation and generate test reports for physicians and their patients. The Company has two laboratories: one in San Francisco California and a second in Santiago Chile. The Company’s first product is an assay of 216 genes that can be used for multiple indications. The test includes multiple genes associated with hereditary cancer neurological disorders cardiovascular disorders and other hereditary conditions. The Company also offers panels for pediatric conditions such as Noonan spectrum disorders and ciliopathies.

Leave a Reply

InVitae Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on InVitae Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.